The potential of cholesteryl ester transfer protein as a therapeutic target.

Date publication

janvier 2016

Journal

Expert opinion on therapeutic targets

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LAGROST Laurent , Pr MASSON David

Tous les auteurs :
Gautier T, Masson D, Lagrost L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26212254

Résumé

Over recent decades, attempts to ascertain the pro-atherogenic nature of plasma cholesteryl ester transfer protein (CETP) and to establish the relevance of its pharmacological blockade as a promising high density lipoproteins-raising and anti-atherogenic therapy have been disappointing.

Mots clés

Animals, Atherosclerosis, etiology, Cardiovascular Diseases, etiology, Cholesterol Ester Transfer Proteins, antagonists & inhibitors, Drug Design, Humans, Molecular Targeted Therapy, Patient Selection, Risk Factors

Référence

Expert Opin. Ther. Targets. 2016 ;20(1):47-59